AC Immune SA ACIU
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $8.00 (+210.1% upside)
Key Stats
- Today's Range
- $2.56 – $2.69
- 50-Day Range
- $2.10 – $2.70
- 52-Week Range
- $2.00 – $4.00
- Volume
- 281K shs
- Average Volume
- 208K shs
- Market Cap
- $255.53 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.63%
- Days to Cover
- 14.20
About AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Related Stocks
Compare head-to-head: ACIU vs NVDA·ACIU vs AAPL·ACIU vs GOOGL·ACIU vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.